Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.
|Articles|March 9, 2010
- December 2009
- Volume 0
Do Insurers Spend Too Much on Administration and Too Little on Care?
Author(s)Onclive Team
Advertisement
Articles in this issue
over 16 years ago
Amgen Honored for Best Pipeline & Best New Drugover 16 years ago
The Effect of New Treatments on Cancer-related Bone Lossover 16 years ago
Exercise Maintains Function, Improves QoL for Patients With Lymphomaover 16 years ago
Continuing Education Opportunities on the Webover 16 years ago
News Briefs & FDA Updatesover 16 years ago
News & Opinionover 16 years ago
Decline in Cancer Deaths No Reason to Get ComplacentAdvertisement
Related to this article
Age, geographic location, transportation barriers, and language and communication barriers may limit patient opportunities to participate in research.
Retrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.
Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.
Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.
Are we ready to “take that fork in the road” and move palliative/supportive care into routine cancer care?
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
Keith Flaherty, MD, FAACR, discusses the 2026 AACR Cancer Progress Report and how the oncology field can build on the report’s findings.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
2
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
3
Dr Calais on Individualizing PSMA-Targeted Therapy Sequencing in Prostate Cancer
4
CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 Inhibition
5